The development is reported of an ultra-rapid, point-of-care diagnostic device which harnesses surface acoustic wave (SAW) biochips, to detect HIV in a finger prick of blood within 10 seconds (samplein-result-out). The disposable quartz biochip, based on microelectronic components found in every consumer smartphone, is extremely fast because no complex labelling, amplification or wash steps are needed. A pocket-sized control box reads out the SAW signal and displays results electronically. High analytical sensitivity and specificity are found with model and real patient blood samples. The findings presented here open up the potential of consumer electronics to cut lengthy test waiting times, giving patients on the spot access to potentially life-saving treatment and supporting more timely public health interventions to prevent disease transmission.Ebola and Zika viruses offer a stark reminder that infectious diseases rank among the gravest threats to human health, and can spread rapidly and unpredictably. New infections will continue to emerge each year, and old enemies re-emerge, increasingly with acquired-drug resistance (e.g. gonorrhoea and HIV). Rapid diagnosis plays a crucial role in any outbreak situation, empowering patients to gain faster access to potentially life-saving treatment, and informing prevention strategies to protect the wider public. However, routine diagnostic tests based on enzyme linked immunosorbent assays (ELISAs) and polymerase chain reaction (PCR) are confined to centralized laboratories often requiring large, sophisticated, costly instrumentation and highly trained staff. Inherent delays occur between taking samples, conveying them to the laboratory, waiting for results to come back and subsequent follow up appointments 1-3 . This means that a patient often has to make multiple visits to a clinic in order to receive treatment, potentially over long distances. This delays prescribing of treatment with increased risk of suffering, mortality, and also incorrect prescription of antimicrobials.Recent policy drivers aim to widen access to testing using so called 'rapid' point-of-care tests (POCT) but the performance and implementation of these tests still remain a challenge 4 . The most common tests based on lateral flow technology are still relatively slow, requiring a 10-20 minute waiting time for results 5 . This exceeds a typical doctor's appointment (8-10 mins in the UK 6 ) necessitating changes to patient pathways within a clinic with additional on-costs and staffing implications. It is also notoriously difficult to interpret a faint lateral flow test line by eye, particularly for non-experts (e.g. self-testers) 1 . Those tests that are currently available are insensitive to recent (acute) infections 7 and lack the ability to automatically capture test results electronically, risking an incorrect reading, missed opportunities to link patients to care pathways and potential data loss for public health (e.g. during an Ebola outbreak) 8 . Alternatively, uneccesary treatment may be initi...